Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Essex Woodlands leads $40.4mm Series C round for Catalyst

Executive Summary

First-time investor Essex Woodlands led the $40.4mm Series C financing for Catalyst Biosciences (redesigns proteases--called Alterases--that target disease-causing proteins). Returning backers Burrill & Co., HealthCare Ventures, Johnson & Johnson Development Corp., Morgenthaler Ventures, Novartis BioVentures, and Sofinnova Ventures also participated. A managing director from Essex joined the company's board. Catalyst says it will now have enough money to support its activities for the next few years, including moving its CB813 Factor VIIa treatment for hemophilia (currently at the preclinical stage) through Phase I/II proof-of-concept studies.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies